triple glp-1/gip/glucagon receptor agonist acting glp 1 parkinson's disease glp-1 gip glucagon clinical trial Current Insights, Advantages and Challenges of Triple GLP-1 / GIP / – New strategies for the treatment

J.LiJ.et al (2018)

Limited clinical data exist supporting L-carnitine's use in the management of mitochondrial dysfunction related to aging and apoptosis, AIDS-related dementia complex, drug-induced anemia, bipolar depression, cachexia, cardiovascular disease, dyslipidemia, dysthymic disorder, fatigue, drug-induced hepatotoxicity, intermittent claudication, migraine prophylaxis, muscle cramps, and drug-induced peripheral neuropathy

A third person claims their hairline moved forward two centimeters in 90 days

Understanding this distinction is essential for appreciating why this combination may produce results beyond what any triple agonist alone can achieve